SCHEMBL3523970

SCHEMBL3523970

CNS(=O)(=O)c1cccc(C(=O)O)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
CYP1A2 P05177 1/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
MMP1 P03956 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
MMP8 P22894 1/20 0.49
MMP13 P45452 1/20 0.49
CA12 O43570 5/20 0.45
CA9 Q16790 5/20 0.45
MAPT P10636 1/20 0.45
ALOX15 P16050 1/20 0.45
ACLY P53396 1/20 0.43
PDK1 Q15118 1/20 0.43
PDK2 Q15119 1/20 0.43
PDK3 Q15120 1/20 0.43
PDK4 Q16654 1/20 0.43
APP P05067 1/20 0.43
WDR5 P61964 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27621339 0.84 TSHR (0.47) TSHRCA1CA2MMP1MMP2
SCHEMBL3527108 0.84 CA1 (0.51) TSHRCYP1A2CA1CA2CA9
SCHEMBL3528899 0.83 CA12 (0.60) TSHRCYP1A2CA1CA2MMP1
SCHEMBL4433906 0.82 CA1 (0.70) TSHRCYP1A2CA1CA2MMP1
SCHEMBL31544300 0.81 TSHR (0.55) TSHRCA1CA2MMP1MMP2
SCHEMBL27046566 0.80 CYP1A2 (0.50) CYP1A2CA1CA2MMP1MMP2
SCHEMBL31494275 0.80 CYP1A2 (0.50) CYP1A2CA1CA2MMP1MMP2
SCHEMBL6153587 0.79 TSHR (0.57) TSHRCA1CA2MMP1MMP2
SCHEMBL11022413 0.79 TSHR (0.57) TSHRCYP1A2CA1CA2MMP1
SCHEMBL3526582 0.78 ALDH1A1 (0.50) TSHRCA1CA2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
CN-1744899-A Piperidine derivatives as CCR5 antagonists SMITHKLINE BEECHAM CORP (US) 2006-03-08 CN disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 TSHR 2546/4885CYP1A2 2156/4885CA1 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.